Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Vanda Pharmaceuticals (VNDA) over the last 13 years, with Q4 2025 value amounting to $1.3 million.

  • Vanda Pharmaceuticals' Change in Inventory rose 109626.17% to $1.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.5 million, marking a year-over-year increase of 1185172.41%. This contributed to the annual value of $3.5 million for FY2025, which is 1185172.41% up from last year.
  • According to the latest figures from Q4 2025, Vanda Pharmaceuticals' Change in Inventory is $1.3 million, which was up 109626.17% from -$32000.0 recorded in Q3 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Change in Inventory peaked at $1.8 million during Q1 2025, and registered a low of -$263000.0 during Q2 2024.
  • For the 5-year period, Vanda Pharmaceuticals' Change in Inventory averaged around $548900.0, with its median value being $385500.0 (2022).
  • Its Change in Inventory has fluctuated over the past 5 years, first plummeted by 13374.69% in 2023, then soared by 647931.03% in 2025.
  • Vanda Pharmaceuticals' Change in Inventory (Quarter) stood at $77000.0 in 2021, then skyrocketed by 1367.53% to $1.1 million in 2022, then plummeted by 62.21% to $427000.0 in 2023, then tumbled by 74.94% to $107000.0 in 2024, then soared by 1096.26% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q4 2025, -$32000.0 for Q3 2025, and $368000.0 during Q2 2025.